ATE396974T1 - Krystallinform gamma von ivabradine-hydrochlorid, verfahren zu dessen herstellung und diesen enthaltende pharamazeutische zusammensetzung - Google Patents

Krystallinform gamma von ivabradine-hydrochlorid, verfahren zu dessen herstellung und diesen enthaltende pharamazeutische zusammensetzung

Info

Publication number
ATE396974T1
ATE396974T1 AT06290328T AT06290328T ATE396974T1 AT E396974 T1 ATE396974 T1 AT E396974T1 AT 06290328 T AT06290328 T AT 06290328T AT 06290328 T AT06290328 T AT 06290328T AT E396974 T1 ATE396974 T1 AT E396974T1
Authority
AT
Austria
Prior art keywords
production
pharmaceutical composition
composition containing
containing same
ivabradine hydrochloride
Prior art date
Application number
AT06290328T
Other languages
English (en)
Inventor
Stephane Horvath
Marie-Noelle Auguste
Gerard Damien
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE396974(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Application granted granted Critical
Publication of ATE396974T1 publication Critical patent/ATE396974T1/de

Links

Classifications

    • G—PHYSICS
    • G04—HOROLOGY
    • G04F—TIME-INTERVAL MEASURING
    • G04F1/00—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers
    • G04F1/04—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers by movement or acceleration due to gravity
    • G04F1/06—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers by movement or acceleration due to gravity by flowing-away of a prefixed quantity of fine-granular or liquid materials, e.g. sand-glass, water-clock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/21—Monitoring or handling of messages
    • H04L51/214—Monitoring or handling of messages using selective forwarding
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/21—Monitoring or handling of messages
    • H04L51/212—Monitoring or handling of messages using filtering or selective blocking

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06290328T 2005-02-28 2006-02-28 Krystallinform gamma von ivabradine-hydrochlorid, verfahren zu dessen herstellung und diesen enthaltende pharamazeutische zusammensetzung ATE396974T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0501989A FR2882555B1 (fr) 2005-02-28 2005-02-28 Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
ATE396974T1 true ATE396974T1 (de) 2008-06-15

Family

ID=34954955

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06290328T ATE396974T1 (de) 2005-02-28 2006-02-28 Krystallinform gamma von ivabradine-hydrochlorid, verfahren zu dessen herstellung und diesen enthaltende pharamazeutische zusammensetzung

Country Status (42)

Country Link
US (3) US7361650B2 (de)
EP (1) EP1707562B1 (de)
JP (1) JP4628974B2 (de)
KR (1) KR100835447B1 (de)
CN (1) CN100402502C (de)
AP (1) AP1956A (de)
AR (1) AR052926A1 (de)
AT (1) ATE396974T1 (de)
BR (1) BRPI0600796B8 (de)
CA (1) CA2537400C (de)
CO (1) CO5770097A1 (de)
CR (1) CR8249A (de)
CU (1) CU23616B7 (de)
CY (1) CY1109010T1 (de)
DE (1) DE602006001312D1 (de)
DK (1) DK1707562T3 (de)
EA (1) EA008465B1 (de)
ES (1) ES2308689T3 (de)
FR (1) FR2882555B1 (de)
GE (1) GEP20084467B (de)
GT (1) GT200600088A (de)
HR (1) HRP20080406T5 (de)
IL (1) IL173959A0 (de)
JO (1) JO2515B1 (de)
MA (1) MA28134A1 (de)
ME (1) ME02747B (de)
MY (1) MY158129A (de)
NO (1) NO338481B1 (de)
NZ (1) NZ545578A (de)
PE (1) PE20061142A1 (de)
PL (1) PL1707562T3 (de)
PT (1) PT1707562E (de)
PY (1) PY0604616A (de)
RS (1) RS50598B (de)
SA (1) SA06270040B1 (de)
SG (1) SG125229A1 (de)
SI (1) SI1707562T1 (de)
TW (1) TWI314143B (de)
UA (1) UA86595C2 (de)
UY (1) UY29406A1 (de)
WO (1) WO2006092492A1 (de)
ZA (1) ZA200601764B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
EP2460797A3 (de) 2006-11-30 2012-12-05 Cadila Healthcare Limited Verfahren zur Herstellung von Ivabradinhydrochlorid
CN101353325B (zh) * 2007-07-27 2011-11-09 上海优拓医药科技有限公司 稳定型盐酸伊伐布雷定结晶及其制备方法
EP2162438A4 (de) 2007-05-30 2011-07-06 Ind Swift Lab Ltd Verfahren zur herstellung von ivabradinhydrochlorid und polymorph daraus
ES2402765T3 (es) 2008-12-22 2013-05-08 Krka, D.D., Novo Mesto Procedimiento de preparación de ivabradina
CN101774969B (zh) 2009-01-13 2012-07-04 江苏恒瑞医药股份有限公司 硫酸伊伐布雷定及其i型结晶的制备方法
WO2010128525A2 (en) 2009-05-04 2010-11-11 Dinesh Shantilal Patel A formulation of ivabradine for treating the cardiovascular disease
EP2534135A2 (de) 2010-02-12 2012-12-19 KRKA, D.D., Novo Mesto Neuartige ivabradinhydrochloridformen
HUP1000245A2 (en) 2010-05-07 2011-11-28 Richter Gedeon Nyrt Industrial process for the production ivabradin salts
TWI499587B (zh) * 2010-06-03 2015-09-11 Jiangsu Hengrui Medicine Co 硫酸伊伐佈雷定及其ｉ型結晶的製備方法
WO2012025940A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Polymorphic form of ivabradine hydrochloride and process for preparation thereof
US9440924B2 (en) 2011-08-02 2016-09-13 Sandoz Ag Acetone solvate of ivabradine hydrochloride
WO2013064427A1 (en) 2011-11-04 2013-05-10 Synthon Bv A process for making crystalline delta-form of ivabradine hydrochloride
EP2589594A1 (de) 2011-11-04 2013-05-08 Urquima S.A. Ivabradin-Hydrochloridform IV
WO2013102919A1 (en) 2011-11-14 2013-07-11 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
CN103183639B (zh) * 2011-12-30 2015-06-17 浙江京新药业股份有限公司 一种稳定的盐酸伊伐布雷定ii晶型及其制备方法
EP2948432B1 (de) 2013-01-24 2018-09-19 Synthon BV Verfahren zur herstellung von ivabradin
ITMI20130416A1 (it) * 2013-03-19 2014-09-20 Chemo Res S L Nuovo polimorfo del cloridrato di ivabradina e metodo per la sua preparazione
HRP20200300T4 (hr) * 2013-03-19 2023-09-15 Chemo Research, S.L. Novi polimorf ivabradin hidroklorida i metoda za njegovu pripremu
CZ2013767A3 (cs) 2013-10-02 2015-04-29 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
ES2672472T3 (es) 2013-12-12 2018-06-14 Synthon Bv Composición farmacéutica que comprende ivabradina amorfa
EP2774606B1 (de) 2014-02-14 2019-01-30 Synthon B.V. Pharmazeutische Zusammensetzung mit Ivabradin-Hydrochlorid-Polymorph IV
CZ2014478A3 (cs) 2014-07-10 2015-09-16 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice
WO2017173458A1 (en) * 2016-04-01 2017-10-05 Swiderski Cyprianna Compositions and methods targeting hcn channels for breathing therapeutics
TR201703066A2 (tr) 2017-02-28 2018-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
EP3366282B1 (de) 2017-02-28 2025-10-01 Sanovel Ilac Sanayi ve Ticaret A.S. Feste orale pharmazeutische zusammensetzungen von ivabradin
US20230181472A1 (en) 2018-10-30 2023-06-15 Amgen Inc. Process of making ivabradine hydrochloride drug product
WO2021126884A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-pEF)
IT202000025312A1 (it) 2020-10-26 2022-04-26 Cambrex Profarmaco Milano S R L Processi per la preparazione di polimorfi di ivabradina hcl
EP4456897A4 (de) 2021-12-31 2025-12-10 Tenax Therapeutics Inc Orale formulierungen von levosimendan zur behandlung von pulmonaler hypertonie mit herzinsuffizienz mit konservierter auswurffraktion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3119874A1 (de) * 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
US4490369A (en) * 1981-05-19 1984-12-25 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Benzazepine derivatives, their pharmaceutical compositions and method of use
FR2681862B1 (fr) * 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
FR2882555B1 (fr) 2007-05-04
SI1707562T1 (sl) 2008-10-31
JO2515B1 (en) 2010-03-17
EP1707562A1 (de) 2006-10-04
GEP20084467B (en) 2008-08-25
RS50598B (sr) 2010-05-07
HK1096659A1 (en) 2007-06-08
CA2537400C (fr) 2009-12-15
MY158129A (en) 2016-08-30
CR8249A (es) 2008-01-21
US20060194963A1 (en) 2006-08-31
US7361650B2 (en) 2008-04-22
PL1707562T3 (pl) 2008-08-29
TW200640872A (en) 2006-12-01
ES2308689T3 (es) 2008-12-01
JP2006241156A (ja) 2006-09-14
DE602006001312D1 (de) 2008-07-10
CU23616B7 (es) 2011-01-27
KR100835447B1 (ko) 2008-06-09
DK1707562T3 (da) 2008-10-13
CO5770097A1 (es) 2007-06-29
CY1109010T1 (el) 2014-07-02
AR052926A1 (es) 2007-04-11
EA008465B1 (ru) 2007-06-29
ZA200601764B (en) 2007-05-30
GT200600088A (es) 2006-10-24
US20090318417A1 (en) 2009-12-24
ME02747B (de) 2010-05-07
WO2006092492A1 (fr) 2006-09-08
NO338481B1 (no) 2016-08-22
PY0604616A (es) 2010-10-01
EP1707562B1 (de) 2008-05-28
HRP20080406T3 (en) 2008-09-30
CN1827602A (zh) 2006-09-06
SA06270040B1 (ar) 2010-03-23
CU20060037A7 (es) 2008-06-30
JP4628974B2 (ja) 2011-02-09
NO20060948L (no) 2006-08-29
AP2006003521A0 (en) 2006-02-28
SG125229A1 (en) 2006-09-29
HRP20080406T5 (en) 2008-11-30
AU2006200857A1 (en) 2010-01-28
PT1707562E (pt) 2008-07-08
CA2537400A1 (fr) 2006-08-28
CN100402502C (zh) 2008-07-16
KR20060095499A (ko) 2006-08-31
US7867996B2 (en) 2011-01-11
UA86595C2 (ru) 2009-05-12
BRPI0600796B8 (pt) 2021-05-25
BRPI0600796A (pt) 2007-08-14
AP1956A (en) 2009-02-18
IL173959A0 (en) 2006-07-05
UY29406A1 (es) 2006-07-31
BRPI0600796B1 (pt) 2019-02-19
NZ545578A (en) 2007-02-23
MA28134A1 (fr) 2006-09-01
TWI314143B (en) 2009-09-01
EA200600320A1 (ru) 2006-08-25
US20080153803A1 (en) 2008-06-26
FR2882555A1 (fr) 2006-09-01
PE20061142A1 (es) 2006-12-30

Similar Documents

Publication Publication Date Title
ATE396974T1 (de) Krystallinform gamma von ivabradine-hydrochlorid, verfahren zu dessen herstellung und diesen enthaltende pharamazeutische zusammensetzung
ATE397933T1 (de) Kristallinform gamma-d von ivabradine- hydrochlorid, verfahren zu dessen herstellung und diesen enthaltende pharmazeutische zusammensetzung
ATE407926T1 (de) Krystallinform beta von ivabradine-hydrochlorid, verfahren zu dessen herstellung und diesen enthaltende pharamazeutische zusammensetzung
ATE397449T1 (de) Kristallinform beta-d von ivabradine-hydrochlorid,verfahren zu dessen herstellung und diesen enthaltende pharmazeutische zusammensetzung
DE502005002316D1 (de) Arylsubstituierte polycyclische amine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE452883T1 (de) KRISTALLINE FORM VON 1-CHLOR-4-(ß-D-GLUCOPYRANOS- 1-YL)-2-Ä4-((S)-TETRAHYDROFURAN-3-YLOXY)- BENZYLÜBENZOL, VERFAHREN ZU DESSEN HERSTELLUNG UND DESSEN VERWENDUNG ZUR HERSTELLUNG VON MEDIKAMENTEN
DE602004028462D1 (de) Rfid-etikett und verfahren zu dessen herstellung
ATE556077T1 (de) Tetrahydrochinolinderivate und verfahren zu deren herstellung
DE602004027978D1 (de) Verbundwerkstoff und Verfahren zu dessen Herstellung
DE602006007336D1 (de) Umspritzte behälter und verfahren zu deren herstellung
DE502005010912D1 (de) Dihydropteridinonderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
ATE433958T1 (de) Glucocorticoid-mimetika, verfahren zu deren herstellung, pharmazeutische zusammensetzungen und deren verwendung
DE602005007419D1 (de) Rohmix-pulverzusammensetzungen und verfahren zu deren herstellung
DE102004021156A8 (de) Flüssigkristalldisplay und Verfahren zu dessen Herstellung
DE602005015506D1 (de) Filmzubereitung und Verfahren zu deren Herstelllung
DE102004022905A8 (de) Flüssigkristalldisplay und Verfahren zu dessen Herstellung
DE50310782D1 (de) Piezoaktor und verfahren zu dessen herstellung
ATE482193T1 (de) Indolonacetamidderivate, verfahren zu deren herstellung und deren verwendungen
ATE496046T1 (de) Arylvinylazacycloalkan-verbindungen und verfahren zu deren herstellung und verwendung
DE112004002104A5 (de) Hochtackige Klebmasse, Verfahren zu deren Herstellung und deren Verwendung
ATE462408T1 (de) Pharmazeutische zusammensetzungen, enthaltend valatograst, und verfahren zu deren herstellung
ATE411308T1 (de) Alpha-kristallform von strontiumranelat, verfahren zu ihrer herstellung und dieser enthaltende pharmazeutische zusammensetzungen
ATE413875T1 (de) Zusammensetzungen enthaltend levetiracetam und verfahren zu deren herstellung.
ATE471930T1 (de) 3-aminocarbazolverbindungen, pharmazeutische zusammensetzungen, die diese enthalten, und verfahren zu deren herstellung
DE602004031350D1 (de) Penamkristall und verfahren zu dessen herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1707562

Country of ref document: EP